U.S. Stock News

If you are wondering whether MSCI's share price still makes sense after its recent run, you are not alone. The stock last closed at US$581.48, with returns of 2.9% over the past month, 0.8% over the past year, 7.4% over three years and 46.4% over five years. These figures may have shifted how some investors think about its risk and growth profile. Recent coverage has focused on MSCI as a key data and index provider for asset managers, ETFs and institutional investors, with attention on how...

Trustmark (TRMK) shares reacted to a packed January 27 update, as investors weighed better than expected adjusted earnings, record contributions from mortgage and wealth management, tighter cost control, and a higher quarterly dividend that lifted the annual payout rate. See our latest analysis for Trustmark. The earnings beat, dividend increase and recent buyback activity have come alongside a 30 day share price return of 10.90% and a 90 day share price return of 13.48%. The 1 year total...

Valvoline (NYSE:VVV) shareholders approved a new 2026 Omnibus Incentive Plan at the company’s Annual Meeting. Investors also elected new directors to the board, updating the company’s leadership and governance structure. Valvoline, traded on the NYSE under the ticker VVV, operates in automotive services and related products, serving drivers who need consistent, repeat maintenance and care for their vehicles. Governance changes such as a refreshed incentive plan and new directors sit...

If you are wondering whether Energizer Holdings is attractively priced right now, you are not alone. The stock has been drawing attention from investors trying to make sense of its current value. The share price closed at US$22.96 recently, with returns of 5.7% over the last 7 days and 15.2% over the last 30 days. However, the 1 year return of negative 26.5% and 5 year return of negative 40.6% present a tougher longer term picture. These mixed returns sit against a backdrop of ongoing...

Darling Ingredients, ticker NYSE:DAR, has experienced a sustained decline in revenue and profitability, with earnings per share weakening over the past three years. The continued drop in earnings highlights operational and market pressures that are now a central focus for investors tracking the company. These trends raise questions around how management will respond and what this could mean for the company’s longer term direction. Shares of Darling Ingredients last closed at $47.86, with...

If you are wondering whether YETI Holdings at around US$46.76 is a fair deal or not, this article will walk through what the current price might be saying about the stock's value. The share price has had mixed returns, with a 1.4% decline over the last week, a 4.3% gain over the past month and year to date, a 26.2% gain over the last year, and a 39.4% loss across five years, which can influence how investors think about both opportunity and risk. Recent attention around YETI has focused on...

If you are wondering whether Urban Edge Properties at around US$19.98 is still offering value or starting to look fully priced, you are asking the right question. The stock shows returns of 4.2% over 7 days, 4.6% over 30 days, 4.6% year to date, 4.3% over 1 year, 39.5% over 3 years and 59.3% over 5 years, which gives useful context before weighing up what you are paying today. Recent market attention has focused on Urban Edge Properties as a US real estate name, with investors weighing up...

Recently, Alkermes was highlighted with a Zacks Rank of #1 (Strong Buy), alongside a 9% upward revision in the Zacks Consensus Estimate for its full-year earnings over the past 90 days, signaling improving analyst expectations. This shift suggests growing confidence in Alkermes’ earnings profile within the Medical sector, as analysts reassess the company’s potential profit trajectory. Next, we’ll look at how this improved analyst sentiment and upgraded earnings outlook could shape Alkermes’...

Avidia Bancorp (AVBC) has wrapped up FY 2025 with fourth quarter revenue of US$26.1 million, net income of US$5.3 million and basic EPS of US$0.29, set against trailing twelve month revenue of US$82.1 million and a TTM net loss of US$3.3 million or EPS of US$0.18. The company has seen revenue move from US$88.5 million in FY 2024 to US$82.1 million on a trailing basis, while earnings have shifted from a profit of US$11.5 million over FY 2024 to a TTM loss of US$3.3 million. This leaves...

PepsiCo (PEP) has put fresh numbers on the board for FY 2025, reporting Q3 revenue of US$23.9b and basic EPS of US$1.90, alongside trailing 12 month revenue of US$92.4b and EPS of US$5.27. These figures sit against a reported net margin of 7.8% compared with 10.2% a year earlier. Over recent quarters the company has seen revenue range from US$17.9b in Q1 2025 to US$27.8b in Q4 2024, while basic EPS moved between US$0.92 and US$2.24. This gives investors a clear look at how headline growth has...

In late January 2026, MINISO Group Holding outlined an accelerated global growth roadmap at its Global Partner Conference in Guangzhou, focusing on immersive store upgrades, proprietary IP development, and expanded international reach, while also reporting a strong fiscal third quarter 2025 that exceeded its own revenue guidance and marked a milestone of more than 8,000 stores worldwide. An interesting development is the launch of the MINISO IP Genius Program, which aims to build...

Analyst reaction to Phase 1 trial progress Piper Sandler and Barclays recently updated their views on CytomX Therapeutics (CTMX) after promising Phase 1 data for varsetatug maseatecan in metastatic colorectal cancer, highlighting renewed investor attention ahead of further clinical readouts. See our latest analysis for CytomX Therapeutics. The share price, which last closed at US$6.07, has seen a 42.82% year to date share price return and a very large 1 year total shareholder return,...

BeOne Medicines (NasdaqGS:ONC) received its first regulatory clearance for BCL2 inhibitor sonrotoclax, supporting clinical development in chronic lymphocytic leukemia. The company extended its collaboration with InSysBio to apply translational modeling for dose selection and cytokine release syndrome risk management in future studies. BeOne Medicines focuses on oncology drug development. Sonrotoclax is now moving into a new regulatory phase that puts more attention on its BCL2 approach in...

AMETEK (AME) has just posted another set of quarterly numbers, with Q3 FY 2025 revenue at US$1,892.6 million and basic EPS of US$1.61 setting the tone for the year so far. The company has seen revenue move from US$1,708.6 million in Q3 FY 2024 to US$1,892.6 million in Q3 FY 2025. Over the same quarters, basic EPS went from US$1.47 to US$1.61, supported by trailing twelve month EPS of US$6.36 on revenue of about US$7.2 billion. Taken together with a trailing net margin of 20.5% versus 19.3% a...

Pfizer (PFE) has just posted its FY 2025 third quarter numbers, reporting revenue of US$16.7b and basic EPS of US$0.62, with trailing twelve month EPS at US$1.73. The company has seen revenue move from US$17.8b in Q4 2024 to US$13.7b in Q1 2025 and US$14.7b in Q2 2025, while quarterly EPS shifted from US$0.07 to US$0.52 and US$0.51 over the same stretch. This feeds into a 15.6% net profit margin over the last 12 months compared with 7.0% a year earlier, giving investors a clearer view of how...

EXL, a global data and AI company, was recently named a Leader for Payer Digital Transformation Services in the ISG Provider Lens Healthcare Digital Services – US 2025 study, marking its fourth consecutive recognition in this category. This repeated Leader status underscores EXL’s combination of artificial intelligence, data, and cloud capabilities with deep healthcare payer expertise to modernize complex operational systems. Next, we’ll examine how this continued leadership in payer digital...

Community Financial System, Inc. has reported past fourth-quarter 2025 results, with net interest income rising to US$133.43 million and net income reaching US$54.42 million, alongside basic and diluted earnings per share from continuing operations of US$1.03. The period also saw net charge-offs fall to US$2,328,000 and the board affirm a quarterly cash dividend of US$0.47 per share, underscoring an emphasis on both credit quality and shareholder returns. We’ll now examine how the...

If you are wondering whether Northrop Grumman at around US$704.98 is offering fair value or stretching expectations, this article is designed to help you make sense of the numbers. The stock has returned 3.9% over the last 7 days, 20.4% over the past month and year to date, 48.7% over 1 year, 63.9% over 3 years, and 152.0% over 5 years. These figures naturally raise questions about what is already priced in and where the risk might sit for new investors. Recent coverage around Northrop...

Investors may be wondering whether Napco Security Technologies, at around US$43.74, is still a sensible entry or addition to a portfolio, or if most of the value story is already reflected in the price. The stock has moved sharply at times, with returns of 13.7% over the last 7 days, 5.7% over the last 30 days, 5.7% year to date, 68.3% over the last year, 27.3% over 3 years, and 198.1% over 5 years. This naturally raises questions about risk and reward at today's level. Recent attention on...

Hess Midstream (HESM) has just wrapped up FY 2025 with fourth quarter revenue of US$404.2 million, basic EPS of US$0.72 and net income of US$93.3 million, capping a year in which trailing twelve month revenue reached US$1.6 billion and EPS came in at US$2.87. Over the last year, revenue has moved from US$1.5 billion to about US$1.6 billion on a trailing basis, while trailing twelve month net income has gone from US$223.1 million to US$352.9 million. This gives investors a clear view of how...

UiPath (NYSE:PATH) is emerging as a leader in agentic AI, a field focused on software agents that can autonomously complete complex, multi step tasks. The company reports strong customer adoption for its agentic AI capabilities, with high retention rates across its user base. UiPath is expanding in the public sector, including work with the U.S. Coast Guard and the Social Security Administration. These developments are drawing attention as potential drivers of investor sentiment toward...

In recent months, analysts have updated their views on LifeStance Health Group, pointing to changing expectations around the company’s prospects. This comes as LifeStance reported revenue growth of 16.34% as of September 30, 2025, underscoring momentum in its top-line performance. With this backdrop of analyst attention and revenue expansion, we’ll examine how these developments shape LifeStance Health Group’s broader investment narrative. Outshine the giants: these 25 early-stage AI...

Graphic Packaging Holding (GPK) has just posted its FY 2025 third quarter numbers, with revenue of about US$2.2 billion, basic EPS of US$0.48 and net income of US$142 million, while trailing 12 month figures show revenue of US$8.6 billion, EPS of US$1.70 and net income of US$511 million. Over the past few quarters, revenue has moved in a tight band from US$2.09 billion in Q4 2024 to between US$2.12 billion and US$2.20 billion through 2025, while quarterly EPS has ranged from US$0.35 to...

W.W. Grainger (GWW) opened FY 2025 with third quarter revenue of US$4.7b and basic EPS of US$6.15, set against a trailing twelve month line of US$17.8b in revenue and EPS of US$35.93. The company has seen quarterly revenue move from US$4.31b in Q2 2024 to US$4.55b in Q2 2025, and from US$4.39b in Q3 2024 to US$4.66b in Q3 2025, while basic EPS has ranged from roughly US$9.59 to US$10.04 across those prior quarters. With a net margin that has eased from 10.8% to 9.7% over the last year, this...